These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 37047315)

  • 1. Cytokine Signatures in Psoriatic Arthritis Patients Indicate Different Phenotypic Traits Comparing Responders and Non-Responders of IL-17A and TNFα Inhibitors.
    Skougaard M; Ditlev SB; Søndergaard MF; Kristensen LE
    Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047315
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of interleukin-17A inhibitor in Japanese patients with psoriatic arthritis compared with tumor necrosis factor-alpha inhibitor.
    Izumiyama T; Mori Y; Oizumi I; Hamada S; Kurishima H; Terui H; Omori-Shimada R; Yamasaki K; Itoi E
    J Orthop Surg (Hong Kong); 2021; 29(2):23094990211012286. PubMed ID: 33938296
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Larid G; Delwail A; Dalle T; Vasseur P; Silvain C; Jégou JF; Morel F; Lecron JC; Gervais E
    Front Immunol; 2022; 13():993363. PubMed ID: 36426370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rho-GTPase pathways may differentiate treatment response to TNF-alpha and IL-17A inhibitors in psoriatic arthritis.
    Rahmati S; O'Rielly DD; Li Q; Codner D; Dohey A; Jenkins K; Jurisica I; Gladman DD; Chandran V; Rahman P
    Sci Rep; 2020 Dec; 10(1):21703. PubMed ID: 33303908
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of synovial tissue polyfunctional T-cells with DAPSA in psoriatic arthritis.
    Wade SM; Canavan M; McGarry T; Low C; Wade SC; Mullan RH; Veale DJ; Fearon U
    Ann Rheum Dis; 2019 Mar; 78(3):350-354. PubMed ID: 30626658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does previous use of tumour necrosis inhibitors change the therapeutic effect of interleukin (IL)-17 or IL-12/23 inhibitors on psoriasis and psoriatic arthritis? Results of a systematic review.
    Xie Y; Liu Y
    Clin Exp Dermatol; 2022 Sep; 47(9):1627-1635. PubMed ID: 35466472
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A potential inflammatory role of IL-31 in psoriatic arthritis: A correlation with Th17 cytokine profile.
    Bautista-Herrera LA; De la Cruz-Mosso U; Román-Fernández IV; Parra-Rojas I; Soñanez-Organis JG; Hernández-Bello J; Morales-Zambrano RA; Villanueva-Quintero GD; Muñoz-Valle JF
    Int J Immunopathol Pharmacol; 2020; 34():2058738420907186. PubMed ID: 32138573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interleukin-17A Is Produced by CD4+ but Not CD8+ T Cells in Synovial Fluid Following T Cell Receptor Activation and Regulates Different Inflammatory Mediators Compared to Tumor Necrosis Factor in a Model of Psoriatic Arthritis Synovitis.
    Xu X; Davelaar N; Mus AM; Asmawidjaja PS; Hazes JMW; Baeten DLP; Vis M; Bisoendial RJ; Prens EP; Lubberts E
    Arthritis Rheumatol; 2020 Aug; 72(8):1303-1313. PubMed ID: 32243724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disease-specific composite measures for psoriatic arthritis are highly responsive to a Janus kinase inhibitor treatment that targets multiple domains of disease.
    Helliwell P; Coates LC; FitzGerald O; Nash P; Soriano ER; Elaine Husni M; Hsu MA; Kanik KS; Hendrikx T; Wu J; Kudlacz E
    Arthritis Res Ther; 2018 Oct; 20(1):242. PubMed ID: 30373651
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of MIF and TNFA in psoriatic arthritis: relationship with Th1/Th2/Th17 cytokine profiles and clinical variables.
    Bautista-Herrera LA; De la Cruz-Mosso U; Morales-Zambrano R; Villanueva-Quintero GD; Hernández-Bello J; Ramírez-Dueñas MG; Martínez-López E; Brennan-Bourdon LM; Baños-Hernández CJ; Muñoz-Valle JF
    Clin Exp Med; 2018 May; 18(2):229-235. PubMed ID: 28965181
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interleukin-17A: a unique pathway in immune-mediated diseases: psoriasis, psoriatic arthritis and rheumatoid arthritis.
    Kirkham BW; Kavanaugh A; Reich K
    Immunology; 2014 Feb; 141(2):133-42. PubMed ID: 23819583
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduction of synovial sublining layer inflammation and proinflammatory cytokine expression in psoriatic arthritis treated with methotrexate.
    Kane D; Gogarty M; O'leary J; Silva I; Bermingham N; Bresnihan B; Fitzgerald O
    Arthritis Rheum; 2004 Oct; 50(10):3286-95. PubMed ID: 15476228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Responsiveness of Serum C-Reactive Protein, Interleukin-17A, and Interleukin-17F Levels to Ustekinumab in Psoriatic Arthritis: Lessons From Two Phase III, Multicenter, Double-Blind, Placebo-Controlled Trials.
    Siebert S; Sweet K; Dasgupta B; Campbell K; McInnes IB; Loza MJ
    Arthritis Rheumatol; 2019 Oct; 71(10):1660-1669. PubMed ID: 31070869
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of ustekinumab versus tumor necrosis factor inhibition on enthesitis: Results from the enthesial clearance in psoriatic arthritis (ECLIPSA) study.
    Araujo EG; Englbrecht M; Hoepken S; Finzel S; Kampylafka E; Kleyer A; Bayat S; Schoenau V; Hueber A; Rech J; Schett G
    Semin Arthritis Rheum; 2019 Feb; 48(4):632-637. PubMed ID: 30037432
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Macrophage-derived cytokine and nuclear factor kappaB p65 expression in synovial membrane and skin of patients with psoriatic arthritis.
    Danning CL; Illei GG; Hitchon C; Greer MR; Boumpas DT; McInnes IB
    Arthritis Rheum; 2000 Jun; 43(6):1244-56. PubMed ID: 10857783
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term persistence of second-line biologics in psoriatic arthritis patients with prior TNF inhibitor exposure: a nationwide cohort study from the French health insurance database (SNDS).
    Pina Vegas L; Hoisnard L; Bastard L; Sbidian E; Claudepierre P
    RMD Open; 2022 Dec; 8(2):. PubMed ID: 36597983
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating Mir-140 and leptin improve the accuracy of the differential diagnosis between psoriatic arthritis and rheumatoid arthritis: a case-control study.
    Cheleschi S; Tenti S; Bedogni G; Fioravanti A
    Transl Res; 2022 Jan; 239():18-34. PubMed ID: 34380068
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improvement from ixekizumab treatment in patients with psoriatic arthritis who have had an inadequate response to one or two TNF inhibitors.
    Kirkham B; Sesin C; Gellett AM; Sprabery AT; Lin CY; Turkiewicz A
    Rheumatology (Oxford); 2021 Sep; 60(9):4367-4372. PubMed ID: 33479721
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Psoriatic arthritis and depressive symptoms: does systemic inflammation play a role?
    De Lorenzis E; Natalello G; Bruno D; Tanti G; Magurano MR; Lucchetti D; Di Mario C; Tolusso B; Peluso G; Gremese E
    Clin Rheumatol; 2021 May; 40(5):1893-1902. PubMed ID: 33009969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Case of Recalcitrant Psoriatic Arthritis to TNF Inhibitors Improved After Administration of Secukinumab, an IL-17A Inhibitor.
    Pelechas E; Memi T; Voulgari PV; Drosos AA
    Rheumatol Ther; 2017 Dec; 4(2):509-513. PubMed ID: 29022197
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.